1. Market Research
  2. > Respiratory Distress Syndrome – Pipeline Review, H1 2013

Respiratory Distress Syndrome – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 86 pages

Respiratory Distress Syndrome – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Respiratory Distress Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Distress Syndrome. Respiratory Distress Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Distress Syndrome.
- A review of the Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Distress Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Respiratory Distress Syndrome - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Respiratory Distress Syndrome Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Respiratory Distress Syndrome 9
Respiratory Distress Syndrome Therapeutics under Development by Companies 11
Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Respiratory Distress Syndrome Therapeutics - Products under Development by Companies 18
Respiratory Distress Syndrome Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Respiratory Distress Syndrome Therapeutics Development 21
Medinox, Inc. 21
GlaxoSmithKline plc 22
Chiesi Farmaceutici SpA 23
Discovery Laboratories, Inc. 24
Teva Pharmaceutical Industries Limited 25
Altor BioScience Corporation 26
ProtAffin Biotechnologie AG 27
Mondobiotech Holding AG 28
Ikaria Inc. 29
Northern Therapeutics, Inc. 30
Faron Pharmaceuticals, Ltd. 31
Clarassance, Inc. 32
Respiratory Distress Syndrome - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
PMX-53 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
dilmapimod - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
lucinactant - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ALT-836 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
IK-6002 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
NOX-100 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
CHF-5633 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
interferon beta-1a - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
interferon beta-1a - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
PA-401 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
lucinactant LS - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
perfluorocarbon - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
CG-100 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
CG-367 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
DasKloster-1000-04 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
DasKloster-014101 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Recombinant Humam Serum Albumin Biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Drug for ARDS - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
CR-0014 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Matrix Metalloprotease And Pro-Inflammatory Cytokine Inhibitors - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Drug Targeting Leptin - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Respiratory Distress Syndrome Therapeutics - Drug Profile Updates 67
Respiratory Distress Syndrome Therapeutics - Discontinued Products 75
Respiratory Distress Syndrome Therapeutics - Dormant Products 76
Respiratory Distress Syndrome - Product Development Milestones 77
Featured News and Press Releases 77
Oct 24, 2012: Discovery Labs Provides Commercial Update For Surfaxin And Afectair 77
Sep 19, 2012: Unigene And Tarix Pharma Announce Completion Of Feasibility Study Of TXA127 78
Sep 06, 2012: Discovery Laboratories Announces Publication Of Surfaxin Preclinical Data In Pediatric Research 79
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 79
May 09, 2012: Discovery Labs Announces Publication Of Comparative Study Of Surfaxin LS And Curosurf In Respiratory Distress Syndrome 80
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 81
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 82
Jun 14, 2011: QRxPharma Completes Comparative Safety Study 82
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 83
Apr 20, 2011: Discovery Labs's KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86



List of Tables

Number of Products Under Development for Respiratory Distress Syndrome, H1 2013 9
Products under Development for Respiratory Distress Syndrome - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Development by Companies, H1 2013 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2013 20
GlaxoSmithKline plc, H1 2013 22
Chiesi Farmaceutici SpA, H1 2013 23
Discovery Laboratories, Inc., H1 2013 24
Teva Pharmaceutical Industries Limited, H1 2013 25
Altor BioScience Corporation, H1 2013 26
ProtAffin Biotechnologie AG, H1 2013 27
Mondobiotech Holding AG, H1 2013 28
Ikaria Inc., H1 2013 29
Northern Therapeutics, Inc., H1 2013 30
Faron Pharmaceuticals, Ltd., H1 2013 31
Clarassance, Inc., H1 2013 32
Assessment by Monotherapy Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Respiratory Distress Syndrome Therapeutics - Drug Profile Updates 67
Respiratory Distress Syndrome Therapeutics - Discontinued Products 75
Respiratory Distress Syndrome Therapeutics - Dormant Products 76



List of Figures

Number of Products under Development for Respiratory Distress Syndrome, H1 2013 9
Products under Development for Respiratory Distress Syndrome - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.